title: The Future of Sublingual Immunotherapy in the United States.
abstract: Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC). The Food and Drug Administration (FDA) in the USA has approved three SLIT tablets for the treatment of AR and ARC in relation to pollen. Specifically, Grastek® and Oralair® are two formulations approved to treat patients suffering with AR/ARC to grass pollen, and Ragwitek™ is a formulation approved to treat patients suffering with AR/ARC to ragweed pollen. Although these approvals provide support for physicians to prescribe SLIT, barriers to prescribing SLIT still remain such as FDA approval for additional formulations, a standard dose and dosing schedule, and cost/insurance coverage. In order to further support the use of SLIT, research is currently being conducted to expand the indication for SLIT to other common comorbidities to AR/ARC. For example, allergic asthma, food allergies, and atopic dermatitis are other diseases which are being explored. The future of SLIT in the USA is unknown; however, education will be necessary for both providers and patients.
authors.affiliation: Division of Allergy, Asthma and Immunology, Department of Medicine, Allegheny General Hospital, Pittsburgh, PA, USA, npleskov@wpahs.org.
authors.forename: Nicole
authors.initials: N
authors.lastname: Pleskovic
authors.forename: Ashton
authors.initials: A
authors.lastname: Bartholow
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Gentile
authors.forename: David P
authors.initials: DP
authors.lastname: Skoner
mesh_terms: D000818:Animals; D001249:Asthma / Q000276:immunology / Q000628:therapy; D003876:Dermatitis, Atopic / Q000276:immunology / Q000628:therapy; D006801:Humans; D065631:Rhinitis, Allergic / Q000628:therapy; D063729:Sublingual Immunotherapy / Q000191:economics / Q000379:methods; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration